01 / ATLAS

What it is

KLOW 80 is a name used for a peptide blend, not a single molecule. The visual material supplied for the atlas lists GHK-Cu, BPC-157, TB-500 and KPV. A label does not independently verify the identity or purity of the contents.

02 / ATLAS

How it works

The components appear in research on the extracellular matrix, cell migration and inflammation. Combining biological hypotheses does not demonstrate complementary effects of the blend in people. [1] [2] [3]

Read the individual entries for GHK-Cu, BPC-157, TB-500 and KPV.

03 / ATLAS

What research shows

The selected sources study individual components. In the research for this entry, we did not identify a controlled clinical trial establishing the efficacy and safety of the KLOW 80 blend.

04 / ATLAS

Study data

Indirect data: experiments on GHK-Cu and fibroblasts, BPC-157 and tendon cells, and KPV and colitis models are not tests of the KLOW 80 combination. [1] [2] [3]

We do not present clinical doses for the blend without a published, verifiable protocol. The quantity printed on a vial is not a recommended dose.

05 / ATLAS

Safety and observed adverse reactions

Each component’s safety, compatibility in the blend and interactions require separate evaluation. Missing adverse-event data for the combination do not mean that risks are absent.

06 / ATLAS

Research status

This entry covers a publicly discussed blend with insufficient clinical evidence for the exact combination. Claims about individual components do not validate the entire blend.

07 / REFERENCES

Studies and sources

  1. Maquart et al. · GHK-Cu in fibroblasts ↗Study of one component, not the blend
  2. Chang et al. · BPC-157 and tendon cells ↗Study of one component, not the blend
  3. Dalmasso et al. · KPV and colitis models ↗Study of one component, not the blend
Back to the atlasFurther information / Contact